Project cooperationUpdated on 29 October 2026

VectorB2B | Clinical Research, Hospital Access & European Funding Partner

Senior Project and Grant Manager at Vector B2B - Drug Developing - Associação Para Investigação Em Biotecnologia

Lisbon, Portugal

About

Your strategic partner for clinical development, hospital-based research and European funding

At VectorB2B, we support biotech, medtech and healthcare innovators from early development to clinical implementation, combining scientific expertise, clinical operations and project management.

CLINICAL RESEARCH & HOSPITAL ACCESS
We provide Site Management Organization (SMO) services directly within hospitals, supporting study set-up, patient recruitment, site coordination and day-to-day trial operations.

Through our hospital network in Portugal, we provide access to a population of approximately 650,000 patients and currently coordinate more than 50 clinical studies and trials across different therapeutic indications.

Our teams work closely with investigators, hospital services, sponsors and CROs, helping ensure efficient study activation, recruitment and execution.

DRUG & MEDTECH DEVELOPMENT SUPPORT
We support companies throughout the development pathway, including:

Development strategy and feasibility assessment
Pre-clinical and clinical project management
Toxicology and GLP services
Medical device studies
Early-phase clinical trials
Phase II–III trials
Phase IV and real-world evidence studies
Regulatory and quality support

Our dedicated project managers can act as a single point of contact, coordinating activities from pre-clinical development through clinical trials.

EUROPEAN FUNDING & CONSORTIUM DEVELOPMENT
VectorB2B also has experience in Horizon Europe and other competitive European funding programmes.

We participate in European consortia and support partners in:

Identification of suitable funding opportunities
Consortium building and partner identification
Proposal development and writing
Work package and project design
Budget preparation
Clinical and pre-clinical planning within funded projects
Project management after grant award

This combination of clinical execution capacity, hospital access and funding expertise allows us to support innovative technologies not only in securing funding, but also in moving from funded R&D projects towards clinical validation and implementation.

We are particularly interested in partnerships with biotech, medtech, pharmaceutical companies, research organisations and European consortia looking for a partner in Portugal for clinical studies, development programmes and collaborative R&D projects.

Topic

Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Destination 5: HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine

Type

Partner seeks Consortium/Coordinator

Organisation

Vector B2B - Drug Developing - Associação Para Investigação Em Biotecnologia

Company (SME)

Lisbon, Portugal

Similar opportunities

Project cooperation
Seeking Partnerships
- Partner seeks Consortium/Coordinator
- Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Shane Brennan
Business Development Manager at Clinical Research Platform
Dublin, Ireland
Project cooperation
Seeking consortium for Horizon Europe calls
- Partner seeks Consortium/Coordinator
- Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
- Destination 5: HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Olha Remeniak
Associate Professor at National Pirogov memorial medical university
Vinnytsia, Ukraine
Project cooperation
Quantitative Systems Pharmacology, Virtual Populations and In Silico Clinical Trials
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Federico Reali
Group Leader at Fondazione The Microsoft Research -University of Trento Centre for Computational and Systems Biology
Rovereto, Italy